Investment

Features

Pro Tools for Pro Traders

Uncover the powerful trading features

Pro Features

Pluang Web Trading

Leverage

Built for Investors

Experience investing with simplified features

Pockets

Recurring Buy

USD Yield

Pluang Cuan

Fees

Safety

Academy

Latest for You

Get up-to-date financial news and investing tips & information

Blog

Find various tips & information to become a knowledgeable investor

News and Analysis

Read the latest information about finance and investment

Learn

Become a smarter investor by learning the basics of investing

Glossary

Learn investment terms to understand investing better

Promo & Referral

Discover exclusive opportunities to level up your investments

Investment Clubs (Coming Soon)

Join hands with like-minded investors to grow wealth together

Press (Coming Soon)

Stay updated with our latest news and media coverage

Support

About Us

Contact

Ask

Career

Tax Reporting Guide

Pluang+

Moderna, Inc. (MRNA) Stock Price Today

Overview

Financial

Technicals

Analysis

Corporate Action

About

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Technical Indicators

Overall Summary

Bearish (18)

Neutral (2)

Bullish (7)

Performance

MRNA ROI

-39.03%

% from 52W High

-58.07%

$69.86

52W Low: $68.28

13 Sep 2024

52W High: $166.61

24 May 2024

News

Benzinga

Moderna, Tyson Foods And Adobe Are Among Top 10 Large Cap Stock Losers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?

The Motley Fool

Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?

The Motley Fool

Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More

Globe Newswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA

Benzinga

Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions